Charles River Laboratories (NYSE: CRL) Beats Q1 2026 EPS Estimates, Reaffirms Full-Year Guidance

Charles River Laboratories International, Inc. (NYSE: CRL) reported first-quarter 2026 EPS of $2.06, beating Wall Street consensus estimates, as steady demand for drug discovery and development services helped offset broader revenue headwinds. The stock was trading at $181.73, down $3.66 (1.97%) on the day, against a previous close of $185.39, suggesting the market digested the beat cautiously within a wider context of muted top-line growth.

Q1 2026 At a Glance

• Revenue: $995.83 million for the quarter ended March 28, 2026
• EPS: $2.06, exceeding analyst estimates per ChartMill
• Full-year guidance: Reaffirmed by management
• Gross margin: 35.0%
• Operating margin: 4.5%
• Net margin: -3.6%, reflecting below-the-line pressures
• Market cap: $9.0 billion | Forward P/E: 14.6x
• Revenue growth (YoY): -0.8%, indicating near-flat top-line trajectory
• 52-week range: $113.89 – $228.88

What Drove the Results

Improved demand for drug discovery and development services was the primary operational driver in the quarter, according to reporting from Finnhub. (NYSE: CRL) has been actively reshaping its portfolio, a strategic effort management referenced when reaffirming full-year guidance — a signal that near-term visibility remains intact despite the modest year-over-year revenue decline.

The -3.6% net margin reflects costs and charges running below the operating line that are compressing reported profitability, even as the 35.0% gross margin and 4.5% operating margin indicate the core business retains reasonable pricing power. The 14.6x forward P/E suggests the market is assigning a measured, though not distressed, valuation to the company's earnings outlook.

Wall Street View

Analyst sentiment on (NYSE: CRL) remained constructive heading into the print. As of May 1, 2026, the consensus stood at 7 Strong Buy, 8 Buy, and 9 Hold ratings, with zero Sell or Strong Sell recommendations. Compared to the prior April 1 snapshot — 7 Strong Buy, 7 Buy, 9 Hold — the Buy tier picked up one additional analyst, reflecting a modest but directionally positive shift in conviction. No price targets were available in the current data.

Investor Takeaway

With Q1 EPS clearing estimates, full-year guidance intact, and a slight improvement in the analyst buy-side count, Charles River Laboratories (NYSE: CRL) presents a reasonably stable near-term picture for investors focused on the contract research and drug development space. The -0.8% revenue growth and -3.6% net margin are worth monitoring as the company continues its portfolio reshaping efforts. Analyst consensus remains net positive, though the meaningful Hold contingent suggests the market is waiting for clearer evidence of top-line reacceleration before extending further conviction.